MARKET

CHMA

CHMA

Chiasma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.400
-0.030
-0.87%
Closed 16:00 04/02 EDT
OPEN
3.400
PREV CLOSE
3.430
HIGH
3.450
LOW
3.360
VOLUME
210.94K
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
2.880
MARKET CAP
143.67M
P/E (TTM)
-3.1150
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CHMA stock price target is 13.40 with a high estimate of 18.00 and a low estimate of 10.00.

EPS

CHMA News

More
  • Edited Transcript of CHMA earnings conference call or presentation 16-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • HC Wainwright & Co. Maintains Buy on Chiasma, Lowers Price Target to $10
  • Benzinga · 03/17 11:47
  • Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/17 02:32

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CHMA

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
More

Webull offers kinds of Chiasma Inc stock information, including NASDAQ:CHMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHMA stock news, and many more online research tools to help you make informed decisions.